Literature DB >> 19223614

Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.

Dana L Swenson1, Kelly L Warfield, Travis K Warren, Candace Lovejoy, Jed N Hassinger, Gordon Ruthel, Robert E Blouch, Hong M Moulton, Dwight D Weller, Patrick L Iversen, Sina Bavari.   

Abstract

Phosphorodiamidate morpholino oligomers (PMOs) are uncharged nucleic acid-like molecules designed to inactivate the expression of specific genes via the antisense-based steric hindrance of mRNA translation. PMOs have been successful at knocking out viral gene expression and replication in the case of acute viral infections in animal models and have been well tolerated in human clinical trials. We propose that antisense PMOs represent a promising class of therapeutic agents that may be useful for combating filoviral infections. We have previously shown that mice treated with a PMO whose sequence is complementary to a region spanning the start codon of VP24 mRNA were protected against lethal Ebola virus challenge. In the present study, we report on the abilities of two additional VP24-specific PMOs to reduce the cell-free translation of a VP24 reporter, to inhibit the in vitro replication of Ebola virus, and to protect mice against lethal challenge when the PMOs are delivered prior to infection. Additionally, structure-activity relationship evaluations were conducted to assess the enhancement of antiviral efficacy associated with PMO chemical modifications that included conjugation with peptides of various lengths and compositions, positioning of conjugated peptides to either the 5' or the 3' terminus, and the conferring of charge modifications by the addition of piperazine moieties. Conjugation with arginine-rich peptides greatly enhanced the antiviral efficacy of VP24-specific PMOs in infected cells and mice during lethal Ebola virus challenge.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223614      PMCID: PMC2681561          DOI: 10.1128/AAC.00936-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding.

Authors:  Ziying Han; Hani Boshra; J Oriol Sunyer; Susan H Zwiers; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Outbreak news. Ebola haemorrhagic fever, Uganda--end of the outbreak.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2008-03-07

Review 3.  Filoviruses: Interactions with the host cell.

Authors:  O Dolnik; L Kolesnikova; S Becker
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

4.  Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

Authors:  St Patrick Reid; Charalampos Valmas; Osvaldo Martinez; Freddy Mauricio Sanchez; Christopher F Basler
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

5.  Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice.

Authors:  T R Gibb; M Bray; T W Geisbert; K E Steele; W M Kell; K J Davis; N K Jaax
Journal:  J Comp Pathol       Date:  2001-11       Impact factor: 1.311

Review 6.  Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.

Authors:  P L Iversen
Journal:  Curr Opin Mol Ther       Date:  2001-06

7.  Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers.

Authors:  D A Stein; D E Skilling; P L Iversen; A W Smith
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2001-10

8.  Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome.

Authors:  Shinji Watanabe; Takeshi Noda; Peter Halfmann; Luke Jasenosky; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

Review 9.  Cell penetrating peptide conjugates of steric block oligonucleotides.

Authors:  Bernard Lebleu; Hong M Moulton; Rachida Abes; Gabriela D Ivanova; Said Abes; David A Stein; Patrick L Iversen; Andrey A Arzumanov; Michael J Gait
Journal:  Adv Drug Deliv Rev       Date:  2007-10-22       Impact factor: 15.470

10.  Peptide-conjugated morpholino oligomers inhibit porcine reproductive and respiratory syndrome virus replication.

Authors:  Deendayal Patel; Tanja Opriessnig; David A Stein; Patrick G Halbur; Xiang-Jin Meng; Patrick L Iversen; Yan-Jin Zhang
Journal:  Antiviral Res       Date:  2007-10-04       Impact factor: 5.970

View more
  30 in total

1.  Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Authors:  Travis K Warren; Kelly L Warfield; Jay Wells; Dana L Swenson; Kelly S Donner; Sean A Van Tongeren; Nicole L Garza; Lian Dong; Dan V Mourich; Stacy Crumley; Donald K Nichols; Patrick L Iversen; Sina Bavari
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

Review 2.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

Review 3.  Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond.

Authors:  Veaceslav Boldescu; Mira A M Behnam; Nikos Vasilakis; Christian D Klein
Journal:  Nat Rev Drug Discov       Date:  2017-05-05       Impact factor: 84.694

Review 4.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

5.  Morpholino treatment improves muscle function and pathology of Pitx1 transgenic mice.

Authors:  Sachchida Nand Pandey; Yi-Chien Lee; Toshifumi Yokota; Yi-Wen Chen
Journal:  Mol Ther       Date:  2013-11-14       Impact factor: 11.454

Review 6.  Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy.

Authors:  Bo Bao; Rika Maruyama; Toshifumi Yokota
Journal:  Intractable Rare Dis Res       Date:  2016-08

7.  Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models.

Authors:  Sufi M Thomas; Bichismita Sahu; Srinivas Rapireddy; Raman Bahal; Sarah E Wheeler; Eva M Procopio; Joseph Kim; Sonali C Joyce; Sarah Contrucci; Yun Wang; Simion I Chiosea; Kira L Lathrop; Simon Watkins; Jennifer R Grandis; Bruce A Armitage; Danith H Ly
Journal:  ACS Chem Biol       Date:  2012-11-09       Impact factor: 5.100

8.  Development of novel bioanalytical methods to determine the effective concentrations of phosphorodiamidate morpholino oligomers in tissues and cells.

Authors:  Frederick J Schnell; Stacy L Crumley; Dan V Mourich; Patrick L Iversen
Journal:  Biores Open Access       Date:  2013-02

Review 9.  Oligonucleotide conjugates for therapeutic applications.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2013-07

Review 10.  Mouse models for filovirus infections.

Authors:  Steven B Bradfute; Kelly L Warfield; Mike Bray
Journal:  Viruses       Date:  2012-09-07       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.